Table 3. Comparisons of baseline characteristics and cumulative exposure durations of antiretroviral drugs between patients with normal and abnormal LSM values.
| Variables | Patients with normal LSMvalues (n = 54, 58.1%) | Patients with abnormal LSMvalues (n = 39, 41.9%) | P-value |
| Age, years | 42.1±9.8 | 43.9±11.1 | 0.421a |
| Gender, male | 52 (96.3) | 36 (92.3) | 0.646b |
| Time period since HIV infection diagnosis, months | 90.5±80.9 | 62.9±35.5 | 0.049a |
| Total duration of cART, months | 62.1±36.7 | 50.5±30.3 | 0.108a |
| CD4+ T lymphocyte counts, cells/mm3 | |||
| At LSM examination | 528.0±239.7 | 468.0±252.3 | 0.247a |
| Nadir | 132.7±99.3 | 173.6±120.6 | 0.082a |
| Plasma HIV-RNA viral load, copies/mL | |||
| Undetectable rangee at LSM examination, yes, n (%) | 46 (85.2) | 30 (76.9) | 0.416c |
| Log10(highest value after the HIV diagnosis) | 5.0±1.0 | 5.0±0.8 | 0.832a |
| Body mass index, kg/m2 | 22.5±3.0 | 22.4±2.9 | 0.860a |
| Alanine aminotransferase, IU/L | 22.9±12.3 | 26.6±17.4 | 0.238a |
| Alkaline phosphatase, mg/dL | 61.8±26.3 | 62.7±17.1 | 0.863a |
| Total bilirubin, mg/dL | 1.0±1.0 | 0.7±0.5 | 0.050a |
| γ-glutamyltranspeptidase, IU/L | 36.4±29.5 | 74.2±63.7 | 0.086a |
| Prothrombin time, INR | 0.93±0.06 | 0.90±0.06 | 0.099a |
| Platelet count, X 103/mm3 | 287±294 | 225±61 | 0.195a |
| Exposed history of antiretroviral drugs, yes, n (%) | |||
| NNRTIs | 33 (61.1) | 21 (53.8) | 0.484c |
| PIs | 36 (66.7) | 22 (56.4) | 0.314c |
| Boosted | 33 (61.1) | 17 (43.6) | 0.094c |
| Unboosted | 18 (33.3) | 13 (33.3) | 1.000c |
| NRTI backbone | |||
| Zidovudine | 39 (72.2) | 29 (74.4) | 0.819c |
| Stavudine | 17 (31.5) | 8 (20.5) | 0.239c |
| Didanosine | 22 (40.7) | 17 (43.6) | 0.784c |
| Abacavir | 16 (29.6) | 7 (17.9) | 0.198c |
NOTE. Data are expressed as mean ± SD or number (percent). aIndependent sample two T-test, bFisher’s exact test, cChi-square test, and dMann-Whitney U-test were used. eThe undetectable range was defined as fewer than 20 copies/mL. LSM, liver stiffness measurement; cART, combined antiretroviral treatment; INR, international normalized ratio; NNRTI, non-nucleoside analogue reverse transcriptase inhibitor; cART, combined antiretroviral treatment; PI, protease inhibitors; NRTI, nucleoside analogue reverse transcriptase inhibitor.